SEC Comment Letter for ZEVRA THERAPEUTICS, INC. (ZVRA) (CIK 0001434647) (ZVRA) — Oct 13, 2016
ZEVRA THERAPEUTICS, INC. (ZVRA) (CIK 0001434647)
Date: Oct. 13, 2016 · CIK: 0001434647 · Accession: 0000000000-16-096868
AI Filing Summary & Sentiment
File numbers found in text: 333-213926
Letter
Mail Stop 4546 October 12 , 2016 Travis C. Mickle , Ph.D. President and Chief Executive Officer KemPharm Inc. 2656 Crosspark Road, Suite 100 Coralville, IA 52241
Re: KemPharm Inc. Registration Statement on Form S-3 Filed October 2, 2016 File No. 333-213926
Dear Dr. Mickle :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at (202) 551 -2544 with any questions.
Sincerely,
/s/ Mary Beth B reslin for
Show Raw Text
Mail Stop 4546 October 12 , 2016 Travis C. Mickle , Ph.D. President and Chief Executive Officer KemPharm Inc. 2656 Crosspark Road, Suite 100 Coralville, IA 52241 Re: KemPharm Inc. Registration Statement on Form S-3 Filed October 2, 2016 File No. 333-213926 Dear Dr. Mickle : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551 -2544 with any questions. Sincerely, /s/ Mary Beth B reslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Matthew P. Dubofsky , Esq. Cooley LLP